India Pharma Outlook Team | Wednesday, 30 September 2026
Pharma pricing comes under siege this month as high-profile drug price caps and regulatory interventions intensify across India and beyond.
The Supreme Court flags steep markups on cancer medicines and presses for a uniform 16 percent margin on all medicines.
State regulators in Karnataka and Maharashtra expose unfair margins on medical devices and hospital consumables, while the NPPA faces industry pushback.
Globally, Sun Pharma joins Most Favored Nation deals aimed at cutting US retail drug costs.
These moves show courts, states and global platforms tightening scrutiny on every layer of the medicine supply chain.
The Supreme Court raises concern over steep markups private hospitals apply to cancer medicines. Justices Vikram Nath and Sandeep Mehta call the practice “carnage” and push for a uniform 16 percent margin on all medicines.
The court questions hospitals that force patients to buy only from in-house pharmacies, opens examination of non-scheduled medicine pricing, and schedules a further hearing on 12 October.
This intervention targets practices that inflate costs for cancer patients and taxpayers under government schemes, potentially setting a national benchmark for hospital medicine margins.
Also Read: Counterfeit Drugs in India: How Packaging Gaps Hurt Supply Chain
Multiple states intensify pressure for broader regulation of medical devices and hospital consumables:
These coordinated actions convert isolated complaints into a multi-state push that strengthens the case for formal price regulation of devices and consumables.
Drug makers reject an NPPA proposal that would place sole legal responsibility for overpricing on manufacturers while shielding retail chemists, hospitals and nursing homes. Industry groups argue the move upends the shared-responsibility balance under the Drugs (Prices Control) Order and burdens compliant producers who already declare accurate MRPs.
Sun Pharma joins eight other manufacturers in Most Favored Nation agreements with the US administration. The deals bring the total to 26 companies covering about 89 percent of the branded drug market.
Sun Pharma also commits 71.4 tons of clindamycin and 6.75 tons of doxycycline to the US Strategic Active Pharmaceutical Ingredients Reserve. The agreements link US prices to the lowest levels paid in other developed countries and support the TrumpRx platform, giving Indian companies a direct role in global pricing frameworks.
This month’s interventions mark more than isolated actions. Courts, state regulators and global platforms are simultaneously tightening the net around markups that patients ultimately pay.
The Supreme Court’s 16 percent margin call, the multi-state push on devices and consumables, the NPPA liability debate, and Sun Pharma’s MFN entry together push pricing scrutiny from reactive enforcement toward systemic redesign. The coming months will test whether these pressures produce lasting rules that protect patients without choking supply.
.jpg)
